WEE1 and neoplasm: Examples of FDA approved multi-kinase inhibitors include Regorafenib for the treatment of CRLM, and Cabozantinib and Sorafenib for the treatment of HCC by blocking the activity of multiple protein kinases that participate in oncogenesis, tumour angiogenesis, and tumour microenvironment formation (13, 14).